SCHEMBL72905

SCHEMBL72905

Brc1cccc(Nc2ccccc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
ALDH1A1 P00352 4/20 0.68
MAPT P10636 2/20 0.68
AR P10275 1/20 0.68
LMNA P02545 2/20 0.58
ALOX12 P18054 2/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 3/20 0.57
KDM4E B2RXH2 2/20 0.57
TSHR P16473 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
CYP3A4 P08684 2/20 0.56
GAA P10253 1/20 0.56
GFER P55789 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
RAPGEF4 Q8WZA2 1/20 0.55
ALOX15 P16050 1/20 0.55
PTGS1 P23219 1/20 0.55
SLC6A2 P23975 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1687027 0.93 RAPGEF4 (0.61) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL29961149 0.93 RAPGEF4 (0.61) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL29961547 0.93 RAPGEF4 (0.61) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL20918447 0.90 ALDH1A1 (0.56) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL14339391 0.89 EGFR (0.54) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL17986638 0.88 RAPGEF4 (0.53) MEN1KMT2AALDH1A1MAPTAR
Diphenylamine SCHEMBL1185801 0.85 HSD17B10 (0.71) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL14137199 0.84 EGFR (0.57) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL12644740 0.83 HSD17B10 (0.60) MEN1KMT2AALDH1A1MAPTAR
SCHEMBL28363060 0.83 ALDH1A1 (0.64) MEN1KMT2AALDH1A1MAPTAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0892789-A1 IRREVERSIBLE INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-01-27 EP claimed
WO-1997038983-A1 IRREVERSIBLE INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1997-10-23 WO claimed
US-20250074925-A1 RARE EARTH COMPLEX SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2025-03-06 US disclosed
EP-4365180-A1 RARE EARTH COMPLEX Tosoh Corporation (JP) 2024-05-08 EP disclosed
CN-117800850-A Compound and organic electroluminescent device, display device 阜阳欣奕华材料科技有限公司 2024-04-02 CN disclosed
CN-117616032-A Rare earth complex 东曹株式会社 2024-02-27 CN disclosed
CN-112341482-B Organic compound, polymer, mixture, composition and electronic device 广东聚华印刷显示技术有限公司 2024-01-09 CN disclosed
CN-117185941-A Compound and organic electroluminescent device, display device 阜阳欣奕华材料科技有限公司 2023-12-08 CN disclosed
US-11839149-B2 Compound and light-emitting device including same SAMSUNG DISPLAY CO., LTD. (KR) 2023-12-05 US disclosed
US-11839149-B2 Compound and light-emitting device including same SAMSUNG DISPLAY CO., LTD. (KR) 2023-12-05 US disclosed
CN-114478270-B Compound and organic electroluminescent device, display device 阜阳欣奕华材料科技有限公司 2023-09-15 CN disclosed
WO-2008118379-A2 AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF β-SECRETASE WYETH (US) 2008-10-02 WO disclosed
WO-2008118379-A2 AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF β-SECRETASE WYETH (US) 2008-10-02 WO disclosed
WO-2003082777-A2 NOVEL GLUCOCORTICOID RECEPTOR LIGANDS KARO BIO AB (SE) 2003-10-09 WO disclosed
EP-0892789-A1 IRREVERSIBLE INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-01-27 EP disclosed
WO-1997038983-A1 IRREVERSIBLE INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1997-10-23 WO disclosed
WO-1995000498-A1 N,N-DIACYLPIPERAZINES MERCK & CO., INC. (US) 1995-01-05 WO disclosed
US-5348955-A Angiotensis II antagonists MERCK & CO., INC. (US) 1994-09-20 US disclosed
US-5292726-A N,N-diacylpiperazines MERCK & CO., INC. (US) 1994-03-08 US disclosed
WO-1992020661-A1 N, N-DIACYLPIPERAZINES MERCK & CO., INC. (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074925-A1 RARE EARTH COMPLEX L1CAM, CHRM1, NPM1 MEN1 140/4885KMT2A 3223/4885ALDH1A1 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.